Clinical Outcomes of Pediatric Acute Lymphoblastic Leukemia in the Bajio Region of Mexico: A Retrospective Cohort Study
- 18 May 2024
- journal article
- research article
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 41 (1) , 60-68
Abstract
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood, and the Hispanic race has the highest incidence worldwide. Disparities in survival rates exist among different regions of the world. Due to this heterogeneity and possible differences in the outcomes within Mexico, the aim of this study was to analyze the clinical outcomes of cohort of pediatric patients with ALL treated in a highly specialized medical unit located in the Bajio region of Mexico. Observational retrospective study of a cohort of pediatric patients with ALL treated in a tertiary-level hospital in the Bajio region of Mexico, between January 2016 and December 2021. A total of 146 patients were included with a median age of 7 years. The 68.5% of patients were at high risk. CNS involvement was present in 2.7%, and Philadelphia chromosome positive in 2%. Cytogenetic analysis was performed in 16.4% patients. The median follow-up of entire cohort was 32 months. The most frequently administered chemotherapy treatment was Total Therapy XV in 79.5% of patients. The complete remission rate was 89%. Refractory disease was present in 2.7%. Induction-related mortality was 8.2%. The relapse rate was present in 26%. The 3-years overall survival was 57.5%, and the 3-years event-free survival was 53.4%. A more aggressive course and worse survival occur in our cohort of pediatric patients with ALL. Strategies should be proposed inside Mexico and other low-middle income countries with the aim of improving the overall survival.Keywords
This publication has 40 references indexed in Scilit:
- Impact of race/ethnicity and language preferences on pediatric ALL survival outcomesCancer Medicine, 2023
- How should childhood acute lymphoblastic leukemia relapses in low‐income and middle‐income countries be managed: The AHOPCA‐ALL study group experienceCancer, 2022
- Measuring disparities in event-free survival among children with acute lymphoblastic leukemia in an academic institute in Oklahoma, 2005–2019Cancer Epidemiology, 2022
- Cytogenetic Risk Stratification of B-Acute Lymphoblastic Leukemia and Its Correlation with Other Prognostic FactorsIndian Journal of Hematology and Blood Transfusion, 2022
- Precision medicine in acute lymphoblastic leukemiaFrontiers of Medicine, 2020
- Disparities in Survival and Health Outcomes in Childhood LeukemiaCurrent Hematologic Malignancy Reports, 2019
- A triple‐probe FISH screening strategy for risk‐stratified therapy of acute lymphoblastic leukaemia in low‐resource settingsPediatric Blood & Cancer, 2018
- Results of Treating Childhood Acute Lymphoblastic Leukemia in a Low-middle Income Country: 10 Year Experience in Northeast MexicoArchives of Medical Research, 2016
- Childhood acute lymphoblastic leukemia in Nicaragua: Long‐term results in the context of an international cooperative programPediatric Blood & Cancer, 2013
- Satelite Symposium V, Meet-the-Professor Sessions I and II, Main Sessions I-IXAnnals of Hematology, 2004